Min Li1, Kurt R Stenmark, Robin Shandas, Wei Tan. 1. Department of Pediatrics and CVP Research, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA.
Abstract
BACKGROUND: Alterations in pulmonary blood flow are often associated with the initiation and progression of pulmonary vascular disease. However, the cellular mechanisms involved in mediating flow effects in the pulmonary circulation remain unclear. Depending on the disease condition, flow may be extremely low or high. We therefore examined effects of pathologically low and high flow on endothelial production of factors capable of affecting pulmonary vascular tone and structure as well as on potential underlying mechanisms. METHODS: Flow effects on pulmonary endothelial release of NO, PGF(1a), ET-1 and TxB(2), on expression of total and phosphorylated eNOS as well as Akt, and on VEGF were examined. Additionally, in a coculture system, effects of flow-exposed endothelial cells on smooth muscle (SM) proliferation and contractile protein were studied. RESULTS: Compared to physiological flow, pathologically high and low flow attenuated endothelial release of NO and PGF(1a), and enhanced release of ET-1. Physiological flow activated the Akt/eNOS pathway, while pathological flow depressed it. Pathologically high flow altered VE-cadherin expression. Pathologically high flow on the endothelium upregulated alpha-SM-actin and SM-MHC without affecting SM proliferation. CONCLUSION: Physiological flow leads to production of mediators which favor vasodilation. Pathological flow alters the balance of mediator production which favors vasoconstriction. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: Alterations in pulmonary blood flow are often associated with the initiation and progression of pulmonary vascular disease. However, the cellular mechanisms involved in mediating flow effects in the pulmonary circulation remain unclear. Depending on the disease condition, flow may be extremely low or high. We therefore examined effects of pathologically low and high flow on endothelial production of factors capable of affecting pulmonary vascular tone and structure as well as on potential underlying mechanisms. METHODS: Flow effects on pulmonary endothelial release of NO, PGF(1a), ET-1 and TxB(2), on expression of total and phosphorylated eNOS as well as Akt, and on VEGF were examined. Additionally, in a coculture system, effects of flow-exposed endothelial cells on smooth muscle (SM) proliferation and contractile protein were studied. RESULTS: Compared to physiological flow, pathologically high and low flow attenuated endothelial release of NO and PGF(1a), and enhanced release of ET-1. Physiological flow activated the Akt/eNOS pathway, while pathological flow depressed it. Pathologically high flow altered VE-cadherin expression. Pathologically high flow on the endothelium upregulated alpha-SM-actin and SM-MHC without affecting SM proliferation. CONCLUSION: Physiological flow leads to production of mediators which favor vasodilation. Pathological flow alters the balance of mediator production which favors vasoconstriction. Copyright 2009 S. Karger AG, Basel.
Authors: Stephen Wedgwood; Calista J Mitchell; Jeffrey R Fineman; Stephen M Black Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-01-17 Impact factor: 5.464
Authors: Leopold Stiebellehner; Maria G Frid; John T Reeves; Robert B Low; Meena Gnanasekharan; Kurt R Stenmark Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-07-11 Impact factor: 5.464
Authors: Michal Schäfer; Cynthia Myers; R Dale Brown; Maria G Frid; Wei Tan; Kendall Hunter; Kurt R Stenmark Journal: Curr Hypertens Rep Date: 2016-01 Impact factor: 5.369
Authors: R Blair Dodson; Paul J Rozance; Carson C Petrash; Kendall S Hunter; Virginia L Ferguson Journal: Am J Physiol Heart Circ Physiol Date: 2013-12-06 Impact factor: 4.733
Authors: Michal Schäfer; Vitaly O Kheyfets; Joyce D Schroeder; Jamie Dunning; Robin Shandas; J Kern Buckner; James Browning; Jean Hertzberg; Kendall S Hunter; Brett E Fenster Journal: Pulm Circ Date: 2016-03 Impact factor: 3.017